CA-BRAIN-CORP
Brain Corp, an artificial intelligence (AI) company creating transformative core technology in robotics, and Tennant Company, today announced the European demonstration of Inventory Scan, a powerful new data capture accessory that will be fitted to Tennant’s autonomous floor scrubbers to autonomously scan and report key detail on in-store inventory.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220428005188/en/
"By adding Inventory Scan to new or existing robotic scrubber fleets, retailers are immediately able to access critical in-store inventory data in near real-time," said Dave Ross, Vice President of Business Development at Brain Corp. "Knowing where an item is, if it’s in stock, if it’s in the correct location, if the price is accurate, and more allows managers to operate stores with a new level of efficiency while providing optimal shopping experiences for their customers. Based on the success we’ve seen in the US with the technology, we are excited to get feedback from those in the European market.”
Utilizing a first-of-its-kind, multi-purpose design, the powerful new scanning accessory will be fitted to Tennant’s floor scrubbers powered by Brain Corp’s BrainOS autonomy software platform. The new, cloud-connected Inventory Scan tower is able to capture data as it moves autonomously around the store. Reports are then delivered to the store managers, providing numerous insights including: verification of pricing accuracy, planogram compliance, product stock levels and product localization. Each function negates the need for time-consuming and potentially inaccurate manual processes, which often lead to lost revenue opportunities, waste caused by overordering and not enough attention given to shoppers.
“The new integrated inventory analytics accessory is filling a much-needed AI and data process gap for retailers,” said Maggie Koester, Global Product Manager at Tennant Company. “What makes this solution compelling is the ability to integrate with retailers’ inventory management systems utilizing their existing floor scrubbers. By adding data collection functionality to these machines, we are dramatically improving how stores operate. Inventory Scan allows retailers to be more efficient and effective by reducing the disruption of labor-intensive manual approaches. Our vision is that data collection and floor care become fully automated so our customers can focus on managing their businesses.”
Interclean 2022 to Host the Unveiling of the Technology in Amsterdam
Inventory Scan will have its European introduction on May 10-13, 2022 at the RAI Centre in Amsterdam, on Brain Corp stand - Hall 7, Booth 108.
"This new product marks the beginning of realizing the next phase in our company's vision and continued growth in Europe as well as the US," said Dr. Eugene Izhikevich, CEO of Brain Corp. "We are actively taking BrainOS-powered robots from primarily task-oriented machines to in-store data acquisition platforms. This delivers critical insights and this will add significant ROI for European retailers as we continue to expand our activity in Europe and beyond."
Brain Corp Sees 100% Year-on-year Growth in European Countries Deploying BrainOS-powered Robots
Partnering with many of the world’s leading OEMs (Original Equipment Manufacturers) including Minuteman, Karcher, Nilfisk and Tennant, autonomous robotic scrubbers, powered by Brain Corp’s AI operating system BrainOS®, are now operational across multiple sectors in 16 European countries.
New countries seeing robotic deployments include Belgium, Denmark, Finland, Luxembourg, Norway and Switzerland. Countries implementing the largest numbers of autonomous robots include France, Spain, Portugal, Italy, Germany, the UK, and the Netherlands.
“There’s no doubt that we’re starting to see the tipping point where the integration of robotics with human teams has gone beyond a novelty and become a practical solution for maintaining sustainable operations,” said Michel Spruijt, SVP International Business at Brain Corp. “We’re seeing significant increases in demand across multiple industry sectors which have been impacted most severely by labor shortages and increased operational strain as a result of the pandemic. Autonomous robotics have proven themselves to be a very effective and welcome solution to these growing problems.”
In 2021, the BrainOS®-powered fleet of autonomous mobile robots hit a major milestone of 500 million square feet covered (46.45 million square meters) autonomously in Europe. In total, over 46,000 hours were given back to workers during the year with the most significant growth coming within retail, logistics, and warehousing sectors.
About Brain Corp
Brain Corp is the global leader in robotic AI software that powers the largest fleet of autonomous mobile robots (AMRs) operating in commercial public spaces. Global OEM partners use the company’s cloud-connected platform, BrainOS®, to create scalable, self-driving robots that are used by end customers to clean floors, move inventory, and sense environmental data - turning manual operations into automated workflows. Fortune 500 brands across multiple verticals benefit from the growing portfolio of BrainOS®-powered robots and our industry-leading privacy, safety and efficiency tools that make managing and scaling automation easier. Brain Corp currently powers more than 20,000 AMRs, representing the largest fleet of its kind in the world.
For more information, visit www.braincorp.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005188/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
